'Remarkable' simultaneous approval of five new products in Japan for Novartis

29 June 2020

The Japanese subsidiary of Swiss pharma giant Novartis (NOVN: VX) today announced that the Ministry of Health, Labor and Welfare (MHLW) has simultaneously approved five new treatment options for Japanese patients.

The drugs in question are:

Tabrecta (capmatinib, formerly INC280), an oral MET inhibitor for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC);
Entresto (sacubitril valsartan sodium hydrate) in chronic heart failure;
Mayzent (siponimod fumaric acid) in secondary progressive multiple sclerosis (MS);
Enerzair (glycopyrronium bromide, indacaterol acetate, mometasone furoate); and
Atectura (indacaterol acetate, mometasone furoate) in different forms of asthma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK